MedPath

REBLOZYL

REBLOZYL

Approved
DIN Number

02505541

Drug Class

Human

Market Date

Nov 23, 2020

Company
HC

bristol-myers squibb canada

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02505541
AIG Number0162498001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
B03XA06 LUSPATERCEPT
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationSubcutaneous
AHFS Classification20:16.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

LUSPATERCEPTActive
Strength: 25 MG / VIAL
Monograph: LUSPATERCEPT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.